Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis Authors: Daisuke Miura, Stephen Nicholls, Anju E Joham, Michael Braude, Chau Thien Tay Published: 2026 ABSTRACT AbstractA 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction–associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids. Peak triglycerides reached 2329 mg/dL (Système International [SI]: 26.3 mmol/L; reference range, <177 mg/dL [SI: <2 mmol/L]). Comorbidities included poorly controlled diabetes, recurrent hypoglycemia, and steatotic liver disease with moderate fibrosis. Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated. This achieved sustained triglyceride normalization to 213 mg/dL (SI: 2.4 mmol/L), weight loss, glycemic improvement, hypoglycemia resolution, improved liver elastography parameters, and insulin cessation without pancreatitis recurrence. This case demonstrates that glucagon-like peptide-1 receptor agonists warrant consideration in treatment-resistant hypertriglyceridemia with prior pancreatitis when conventional therapy fails, challenging traditional contraindications in carefully selected patients under multidisciplinary care.Keywords: hypertriglyceridemia, pancreatitis, metabolic dysfunction–associated steatotic liver disease, incretin-based combination therapies Introduction Hypertriglyceridemia represents the third leading cause of acute pancreatitis after gallstones and alcohol [1], accounting for ∼20% of the cases [2]. Systematic review evidence demonstrates that hypertriglyceridemia-induced acute pancreatitis (HTGP) is associated with worse pancreatitis severity, higher mortality rates (20% vs 15%), and recurrence rates (up to 65% vs 23%) compared with other etiologies [2]. Acute treatment comprises plasmapheresis and insulin infusion, with a transition to long-term lipid-lowering therapies [3]. Chronic prevention relies predominantly on lifestyle management (including dietary fat restriction, alcohol cessation, and regular exercise) and fibrate therapy (fenofibrate and gemfibrozil) as first-line pharmacology treatment, with adjunctive therapies including statins, omega-3 fatty acids, and niacin providing additional lipid-lowering support [4]. However, a substantial subset exhibits inadequate reduction despite maximized combination therapy, leading to recurrent pancreatitis and a critical management gap. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin-based therapies originally developed for type 2 diabetes management. Beyond their glycemic effects, these agents have favorable lipid profile effects with large-scale cardiovascular outcome trials confirming substantial triglyceride reductions alongside established cardiovascular mortality benefits [5]. However, early postmarketing surveillance and observational studies raised safety concerns regarding potential pancreatitis adverse events, creating a clinical paradox that has historically precluded their therapeutic consideration in patients with pancreatitis [6]. Recent mechanistic studies and updated safety analyses suggested concerns of GLP-1RA-induced pancreatitis may be overstated, warranting reconsideration of their therapeutic potential in those with refractory hypertriglyceridemia [7, 8]. Herein, we present a case of recurrent HTGP with triglyceride levels refractory to statin–fenofibrate combination, where subsequent GLP-1RA introduction achieved sustained triglyceride normalization, illustrating an innovative approach for treatment-resistant hypertriglyceridemia management. Case presentation A 39-year-old Chinese man with complex metabolic syndrome was first evaluated in the Monash Health multidisciplinary metabolic dysfunction–associated steatotic liver disease (MASLD) clinic by a hepatologist, endocrinologist, and dietitian in October 2022. His medical history was significant for type 2 diabetes mellitus (T2DM) diagnosed at age 29, premature ischemic heart disease with 2 coronary stents, dyslipidemia with severe hypertriglyceridemia and recurrent HTGP, all originally diagnosed in China. Of 6 lifetime episodes of HTGP, 2 occurred in China and 4 following his arrival in Australia since 2016. MASLD was diagnosed in 2017 by ultrasound. His medication regimen at the time of the October 2022 MASLD clinic review comprised ezetimibe 10 mg daily, simvastatin 80 mg daily, fenofibrate 145 mg daily, fish oil 9 g daily, metoprolol 23.75 mg daily, perindopril 4 mg daily, metformin 1000 mg twice daily, empagliflozin 10 mg daily, biphasic isophane insulin twice daily (20 units in the morning, 40 units in the evening), and aspirin 100 mg daily. There was a strong family history of metabolic disease, with his mother developing ischemic heart disease in her 60s in the setting of dyslipidemia, and his father having T2DM. He worked as plasterer and was an ex-smoker. Diagnostic assessment At the October 2022 index clinic review, examination revealed a body mass index (BMI) of 27.4 kg/m2 (Asian-specific threshold for obesity: ≥25.0 kg/m2) with no features of lipodystrophy. Total cholesterol was 209 mg/dL (Système International [SI]: 5.4 mmol/L; reference range, <213 mg/dL [SI: <5.5 mmol/L]); triglyceride was 399 mg/dL (SI: 4.5 mmol/L; reference range, <177 mg/dL [SI: <2.0 mmol/L]), hemoglobin A1c (HbA1c) was 8.3% (SI: 67 mmol/mol; target <7% [SI: <53 mmol/mol]), and urine albumin:creatinine ratio was 215 mg/g (SI: 24.3 mg/mmol; reference range, <30 mg/g [SI: <2.5 mg/mmol]). Transient elastography showed a liver stiffness of 9.1 kPa (reference range, <5.0 kPa), suggestive of moderate fibrosis. The controlled attenuation parameter was 329 dB/m (reference range, <236 dB/m), indicating severe steatosis. Alanine transaminase was elevated at 86 U/L (reference range, 5-40 U/L), gamma-glutamyl transferase 54 U/L (reference range, 5-50 U/L), with normal alkaline phosphatase and bilirubin. Treatment Dietary counseling was provided by the treating dietitian, emphasizing alcohol abstinence, a Mediterranean diet with restriction of saturated fat and simple carbohydrates, alongside coffee consumption which has emerging evidence for hepatoprotective benefit in MASLD. Formal physical activity was deferred given his occupational physical demands. Insulin was progressively titrated by the treating endocrinologists, with escalation of biphasic isophane insulin to a maximum total daily dose of 66 units and empagliflozin to 25 mg daily. Despite these interventions, weight remained stable throughout follow-up and glycemic control remained suboptimal, with HbA1c reaching 8.2% (SI: 66 mmol/mol) in 2023 (Table 1), complicated by recurrent hypoglycemic episodes that compromised both occupational function and quality of life. Table 1Longitudinal anthropometric and metabolic parameters across hospital admissions for HTGP and the MASLD clinic, before and after semaglutide initiationHospital admissions for HTGPOutpatient MASLD clinic—presemaglutideOutpatient MASLD clinic—postsemaglutideParameter (reference range)1st admission July 20162nd admission December 20183rd admission April 20214th admission September 2022Index MASLD review October 2022December 2023June 2024August 2024 Semaglutide commencedDecember 2024June 2025Weight (kg)ND9081.782.58585.3ND84.176.375.5Body mass index (kg/m2) (Asian-specific obesity threshold ≥25.0 kg/m2)ND 27.8 26.5 26.8 27.6 27.7ND 27.324.624.5Total daily insulin dose (units)424254606060ND6000HbA1c (target <7% [SI: <53 mmol/mol]) 8.3% (SI: 67 mmol/mol) 10.7% (SI: 93 mmol/mol) 7.2% (SI: 55 mmol/mol) 8.3% (SI: 67 mmol/mol) 8.3% (SI: 67 mmol/mol) 8.2% (SI: 66 mmol/mol) ND 7.7% (SI: 61 mmol/mol) 6.7% (SI: 50 mmol/mol) 7.6% (SI: 60 mmol/mol) Total cholesterol (reference range, <213 mg/dL [SI: <5.5 mmol/L]) 325 mg/dL (SI: 8.4 mmol/L) 325 mg/dL (SI: 8.4 mmol/L) 321 mg/dL (SI: 8.3 mmol/L) 271 mg/dL (SI: 7.0 mmol/L) 209 mg/dL (SI: 5.4 mmol/L)159 mg/dL (SI: 4.1 mmol/L)ND124 mg/dL (SI: 3.2 mmol/L)ND124 mg/dL (SI: 3.2 mmol/L)Triglycerides (reference range, <177 mg/dL [SI: <2.0 mmol/L]) 2197 mg/dL (SI: 24.8 mmol/L) 1993 mg/dL (SI: 22.5 mmol/L) 1452 mg/dL (SI: 16.4 mmol/L) 2329 mg/dL (SI: 26.3 mmol/L) 399 mg/dL (SI: 4.5 mmol/L) 735 mg/dL (SI: 8.3 mmol/L) 823 mg/dL (SI: 9.3 mmol/L) 372 mg/dL (SI: 4.2 mmol/L) ND 213 mg/dL (SI: 2.4 mmol/L) Bold text denotes abnormal values, with International System of Units (SI) values provided in parentheses. The thin gray column indicates the timing of semaglutide initiation (commenced August 2024); columns to the left are presemaglutide and columns to the right are postsemaglutide. Low-density lipoprotein cholesterol and liver enzymes (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, and alkaline phosphatase) were not consistently measured across all time points and are therefore not reported in this consolidated table; LDL cholesterol could also not be calculated during episodes of severe hypertriglyceridemia. Triglyceride levels shown for hospital admissions refer to levels taken on admission. Asian-specific BMI reference range: Normal 18.5-22.9 kg/m2; At Risk 23.0-24.9 kg/m2; Obesity Class I 25.0-29.9 kg/m2; Obesity Class II ≥30.0 kg/m2.Abbreviations: HTGP, hypertriglyceridemia-induced pancreatitis; MASLD, metabolic dysfunction–associated steatotic liver disease; ND, no data; SI, Système International. Longitudinal anthropometric and metabolic parameters across hospital admissions for HTGP and the MASLD clinic, before and after semaglutide initiation Bold text denotes abnormal values, with International System of Units (SI) values provided in parentheses. The thin gray column indicates the timing of semaglutide initiation (commenced August 2024); columns to the left are presemaglutide and columns to the right are postsemaglutide. Low-density lipoprotein cholesterol and liver enzymes (alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, and alkaline phosphatase) were not consistently measured across all time points and are therefore not reported in this consolidated table; LDL cholesterol could also not be calculated during episodes of severe hypertriglyceridemia. Triglyceride levels shown for hospital admissions refer to levels taken on admission. Asian-specific BMI reference range: Normal 18.5-22.9 kg/m2; At Risk 23.0-24.9 kg/m2; Obesity Class I 25.0-29.9 kg/m2; Obesity Class II ≥30.0 kg/m2. Abbreviations: HTGP, hypertriglyceridemia-induced pancreatitis; MASLD, metabolic dysfunction–associated steatotic liver disease; ND, no data; SI, Système International. The patient was concurrently referred to the Victorian Heart Institute lipid clinic, where hypertriglyceridemia remained uncontrolled despite maximal lipid-lowering therapy. Lipid-lowering therapy was rationalized with transition from simvastatin 80 mg to atorvastatin 80 mg for optimized low-density lipoprotein (LDL) reduction. Follow-up coronary angiography demonstrated significant left anterior descending artery disease and a chronically occluded right coronary artery, with the patient listed for coronary artery bypass grafting. At that review in June 2024, triglycerides were 823 mg/dL (SI: 9.3 mmol/L) and high-density lipoprotein cholesterol 27 mg/dL (SI: 0.7 mmol/L; reference range, >39 mg/dL [SI: >1.0 mmol/L]). Low-density lipoprotein cholesterol could neither be calculated in the setting of severe hypertriglyceridemia nor be measured directly. Nearly 2 years on from the index clinic review, in August 2024, the MASLD clinic's endocrinologist initiated semaglutide and titrated to the maximum dose of 1 mg weekly over a course of 3 months. Outcome and follow-up With the initiation of semaglutide, body weight decreased from a baseline of 84.1 kg (BMI 27.3 kg/m2) to 75.5 kg (BMI 24.5 kg/m2) over 10 months (−8.6 kg; −10.2%). Glycemic control improved markedly, with HbA1c declining to 6.7% (SI: 50 mmol/mol) 4 months after starting semaglutide. This allowed for complete cessation of insulin while continuing metformin 2 g daily, empagliflozin 25 mg daily, and semaglutide 1 mg weekly. Hypoglycemic episodes resolved completely. By the subsequent review, a year later in June 2025, HbA1c had risen to 7.6% (SI: 60 mmol/mol) in the context of dietary relapse; however, this remained improved relative to presemaglutide values, and insulin was not restarted given sustained weight loss and reinforcement of dietary measures. His lipid profile demonstrated substantial improvement, with triglycerides reduced to a historical nadir of 213 mg/dL (SI: 2.4 mmol/L) alongside total cholesterol of 124 mg/dL (SI: 3.2 mmol/L; Fig. 1, Table 1). Notably, he experienced no recurrence of pancreatitis during follow-up. Temporal changes in HbA1c, weight, and triglycerides before and after semaglutide initiation. Longitudinal changes in serum triglycerides, glycated hemoglobin (HbA1c), and body weight from the index visit at the Monash Health multidisciplinary MASLD clinic to most recent follow-up. The horizontal axis indicates time in months relative to the index visit (Month 0). The vertical dashed line indicates the timing of subcutaneous semaglutide initiation (Month 22). Triglyceride concentrations are presented in conventional units (mg/dL) and SI units (mmol/L), with the secondary axis derived by exact linear conversion (mmol/L = mg/dL ÷ 88.57). HbA1c is reported in National Glycohemoglobin Standardization Program units (%); equivalent International Federation of Clinical Chemistry values are 67 mmol/mol (8.3%), 66 mmol/mol (8.2%), 61 mmol/mol (7.7%), 50 mmol/mol (6.7%), and 60 mmol/mol (7.6%). Reference thresholds are indicated by horizontal dotted lines: triglycerides <177 mg/dL (SI: <2.0 mmol/L) and HbA1c < 7% (53 mmol/mol). Y-axis ranges for HbA1c (6.5-9.5%) and weight (70-90 kg) have been truncated to facilitate visualization of clinically relevant changes; the triglyceride axis is presented in full from zero. Marker symbols: circles, triglycerides; squares, HbA1c; triangles, weight. Abbreviations: HbA1c, glycated hemoglobin; SI, Système International. MASLD also showed improvement on repeated assessment. Hepatic transaminases normalized, and transient elastography showed liver stiffness reduced to 5.2 kPa and the controlled attenuation parameter improved to 297 dB/m. Discussion This case demonstrates the therapeutic potential of GLP-1RAs in managing treatment-resistant hypertriglyceridemia. Hypertriglyceridemia affects 15% to 20% of adults globally with severe elevations (>1000 mg/dL [SI: >11.4 mmol/L]) conferring substantial pancreatitis risk [9]. Triglyceride hydrolysis by pancreatic lipase generates excessive free fatty acids, causing direct acinar lipotoxicity, acinar necrosis, and microcirculatory disruption via trypsinogen activation [1]. Genetic susceptibility, particularly “cystic fibrosis transmembrane conductance regulator” mutations (26.1% vs 1.3% in controls), may further predispose to HTGP [10]. Acute HTGP management centers on rapidly lowering triglycerides. Plasmapheresis removes triglyceride-rich lipoproteins directly from circulation and can lower levels by 50% to 80% in a single session [11], but availability and cost limit access. Intravenous insulin activates lipoprotein lipase and suppresses hepatic very-LDL (VLDL) production [12]; it is inexpensive and widely available but requires close glucose monitoring. Neither addresses the underlying lipoprotein metabolic dysfunction, leaving patients vulnerable to recurrence. Chronic management combines lifestyle modifications with pharmacotherapy targeting distinct metabolic pathways. Weight reduction, dietary fat restriction, and alcohol cessation are foundational but often insufficient. Fibrates activate peroxisome proliferator–activated receptor-α, upregulating lipoprotein lipase [13]; statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase, secondarily decreasing VLDL production [14]; niacin inhibits hepatic diacylglycerol acyltransferase-2, suppressing VLDL synthesis [15]; and omega-3 fatty acids downregulate hepatic VLDL–triglyceride synthesis and enhance β-oxidation [16]. Substantial patient subsets nonetheless exhibit treatment resistance, necessitating approaches targeting alternative pathways. Emerging agents, such as angiopoietin-like protein 3 inhibitors or antisense oligonucleotides targeting apolipoprotein C-III, show promising efficacy in clinical trials but remain investigational and not yet widely available [17]. In contrast, GLP-1RAs are an established class with widespread availability and extensive safety data from diabetes management. Large-scale cardiovascular outcome trials have consistently demonstrated cardioprotective effects, and a recent meta-analysis of 32 884 participants reported significant triglyceride reductions of 6.78% alongside other cardiovascular benefits [18]. Glucagon-like peptide-1 receptor agonists reduce triglycerides through several pathways. Slowing of gastric emptying and intestinal lipid absorption leads to reduced postprandial chylomicron excursions. Glucagon-like peptide-1 signaling directly inhibits intestinal chylomicron secretion from enterocytes, further dampening triglyceride peaks. The weight loss induced by GLP-1RAs can also improve hepatic insulin sensitivity, suppress VLDL production, and reduce hepatic steatosis [19]. These effects converge to lower both fasting and postprandial triglycerides, which are key drivers of pancreatitis risk. Despite these mechanistic benefits, use of GLP-1RAs in patients with a history of pancreatitis has historically been approached with caution. Early postmarketing pharmacovigilance reports raised concern for an association between incretin-based therapies and pancreatitis, with proposed mechanisms involving pancreatic ductal cell proliferation, increased enzyme secretion, and altered gallbladder motility [20], resulting in mandatory Food and Drug Administration safety labeling updates in 2009. However, subsequent large observational studies and real-world data have consistently failed to confirm a causal link, challenging these safety signals [6]. In fact, recent analyses suggest a lower incidence of pancreatitis in GLP-1RA users compared with other glucose-lowering therapies, possibly reflecting their beneficial metabolic effects [7]. The Food and Drug Administration and European Medicines Agency have since noted that assertions of causal associations are inconsistent with current evidence, supporting reconsideration of contraindications in appropriately selected patients when other therapeutic options are limited. This case demonstrates triglyceride normalization following initiation of semaglutide after failure of intensive conventional therapy, including fibrates, high-dose statins, and omega-3 supplementation, with no further episodes of pancreatitis observed during the period of GLP-1RA therapy to date. Notably, a recent case report by Guralwar et al [21] similarly demonstrated successful use of incretin-based therapy in HTGP using liraglutide, followed by tirzepatide. Both cases support incretin-based agonists as adjuncts to conventional lipid-lowering regimens, acting through triglyceride metabolism, weight regulation, and glycemic control. This report has several limitations, including relatively short follow-up, which limits assessment of long-term durability of triglyceride reduction and prevention of recurrent pancreatitis. Additionally, formal genetic evaluation of hypertriglyceridemia and lipoprotein phenotyping were not performed. However, a monogenic etiology was considered unlikely given the absence of lipodystrophic features and onset in the context of poorly controlled T2DM. The coexistence of premature ischemic heart disease and severe hypertriglyceridemia raises the possibility of an underlying polygenic or combined lipid disorder, such as familial combined hyperlipidemia [22]. Lipoprotein electrophoresis and apolipoprotein profiling would have enabled more precise phenotyping and risk stratification and are recommended in similar cases. While the evidence remains preliminary, the convergence of mechanistic plausibility, contemporary safety data, and clinical experience makes a compelling case for prospective evaluation of GLP-1RAs and emerging incretin-based combination therapies in refractory hypertriglyceridemia. In the interim, these agents warrant consideration as adjunctive therapy to prevent recurrent pancreatitis in carefully selected patients under close expert supervision. Learning points HTGP, the third most common cause of acute pancreatitis, carries higher recurrence rates and greater severity than other etiologies, necessitating preventive strategies beyond acute management. HTGP, the third most common cause of acute pancreatitis, carries higher recurrence rates and greater severity than other etiologies, necessitating preventive strategies beyond acute management. Plasmapheresis and insulin infusion rapidly lower triglycerides but do not modify the underlying metabolic dysfunction. Plasmapheresis and insulin infusion rapidly lower triglycerides but do not modify the underlying metabolic dysfunction. Conventional lipid-lowering therapies often achieve only modest triglyceride reductions and are frequently insufficient in severe disease despite maximal combination regimens. Conventional lipid-lowering therapies often achieve only modest triglyceride reductions and are frequently insufficient in severe disease despite maximal combination regimens. GLP-1RAs and emerging incretin-based combination therapies target multiple triglyceride metabolism pathways, a mechanistic advantage over single-target therapies. GLP-1RAs and emerging incretin-based combination therapies target multiple triglyceride metabolism pathways, a mechanistic advantage over single-target therapies. Under close supervision, these agents warrant consideration as adjunctive therapy in treatment-resistant hypertriglyceridemia when conventional regimens fail. Under close supervision, these agents warrant consideration as adjunctive therapy in treatment-resistant hypertriglyceridemia when conventional regimens fail. Contributors All authors made individual contributions to the work. C.T.T., M.B., A.E.J., and S.N. were involved in the diagnosis and clinical management of the patient. D.M. collated and interpreted the clinical data and drafted the manuscript. All authors reviewed the manuscript for intellectual content and approved the final version. Abbreviations body mass index glucagon-like peptide-1 receptor agonist hemoglobin A1c hypertriglyceridemia-induced pancreatitis low-density lipoprotein metabolic dysfunction–associated steatotic liver disease no data Système International type 2 diabetes mellitus Contributor Information Daisuke Miura, Department of Endocrinology, Monash Health, Clayton, VIC 3168, Australia. Stephen Nicholls, Victorian Heart Institute, Monash University, Clayton, VIC 3168, Australia. Anju E Joham, Department of Endocrinology, Monash Health, Clayton, VIC 3168, Australia; Monash Centre for Health Research and Implementation, Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia. Michael Braude, Department of Gastroenterology and Hepatology, Monash Health, Clayton, VIC 3168, Australia; School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia. Chau Thien Tay, Department of Endocrinology, Monash Health, Clayton, VIC 3168, Australia; Monash Centre for Health Research and Implementation, Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia. Funding No public or commercial funding was received for this manuscript. Disclosures None declared. Informed patient consent for publication Signed informed consent obtained directly from the patient. Data availability Original data generated and analyzed during this study are included in this published article. References Associated Data Data Availability Statement Original data generated and analyzed during this study are included in this published article.